Higher Plasma Levels of Endocannabinoids and Analogues Correlate With a Worse Cardiometabolic Profile in Young Adults
Authors' conclusion
Our findings show that the plasma levels of eCBs and their analogues are related to higher levels of adiposity and worse cardiometabolic profile.
Study context
- Population
- Young adults (age 22.1 ± 2.2 years, 67% women)
- Participants
- 133 adults
- Outcome
- Relationship of fasting plasma eCBs and analogues with body composition and cardiometabolic risk factors
Main finding
As reported in the abstract
Correlations of plasma eCBs and analogues with adiposity, BAT and cardiometabolic risk factors
Endocannabinoids (eCBs) and several eCB analogues positively correlated with adiposity and traditional cardiometabolic risk factors (eg, serum insulin and TG)
all r ≥ 0.17 and P ≤ .045
2-arachidonoyl glycerol and N-pentadecenoylethanolamine negatively correlated with brown adipose tissue (BAT) volume and glucose uptake
all r ≤ −0.17 and P ≤ .047
Observational data: associations, not effects.
Original publication
Higher Plasma Levels of Endocannabinoids and Analogues Correlate With a Worse Cardiometabolic Profile in Young Adults. J Clin Endocrinol Metab. Published 15 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →